Showing results (411-420 of 553) with videos related to

Sort By:
Pageof 56
Leukemia & Lymphoma|December 8, 2022
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignanciesBilal Tariq, Ying C Ou, Jennifer C Stern, et al.
Carcinogenesis|May 8, 2012
Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed populationMartha L Slattery, Esther M John, Gabriela Torres-Mejia, et al.
Leukemia|November 1, 1991
In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cellsM Aglietta, L De Felice, A Stacchini, et al.
American Journal of Public Health|July 31, 2024
Identification of Priorities for Colorectal Cancer Screening Interventions Among US Hispanic/Latino PopulationsR Blake Buchalter, Mariana C Stern, Joel Sanchez Mendez, et al.
Ejhaem|February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United StatesAnthony Mato, Boxiong Tang, Soraya Azmi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2024
Prostate Cancer Disparities in Clinical Characteristics and Survival among Black and Latino Patients Considering Nativity: Findings from the California Cancer RegistryAlexis R Freedland, Joel Sanchez Mendez, Lihua Liu, et al.
American Journal of Human Genetics|February 1, 1991
Two frameshift mutations in the cystic fibrosis geneM C Iannuzzi, R C Stern, F S Collins, et al.
Biochimica Et Biophysica Acta|March 15, 2003
Subdomain organization and catalytic residues of the F factor TraI relaxase domainLara M Street, Matthew J Harley, Jennifer C Stern, et al.
Environmental Science & Technology|May 15, 2026
Volatilized Ammonia Supports Subterranean Ecosystems with Unusual Nitrogen Isotopic SignaturesMackenzie B Best, Scott D Wankel, Heather V Graham, et al.
Anti-Cancer Drugs|April 20, 2004
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)Klaus Mross, Max E Scheulen, Thomas Licht, et al.
Pageof 56